BI 1015550

Research use only, not for human use.

Nerandomilast (BI 1015550) is an orally active PDE4B inhibitor with IC50 of 7.2 nM. BI 1015550 has potential applications in inflammation, allergic diseases, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD) with a good safety profile.

Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD).

——

Animal Model:Rats.Dosage:0, 0.3, 1.0 and 3.0 mg/kg.Administration:Oral gavage; single dose.Result:Had minimal toxic and side effects on the intestines and stomach of rats, demonstrating biosafety.Animal Model:Male Suncus Murinus and Wistar rats; mice.Dosage:0.01, 0.1, 0.3, 1.0, 2.5 or 12.5 mg/kg.Administration:Oral gavage; single dose or twice daily for 6 days.Result:Effectively improved inflammation in lung tissue and reduced the pro-inflammatory factor TNF-α release.

——

Angiogenesis

PDE

PDE

——

——

1423719-30-5

448.97

C20H25ClN6O2S

>98% (HPLC)

In Vitro:?DMSO : 10 mg/mL (22.27 mM; Ultrasonic (<60°C)

N(C1=C2C(=NC(=N1)N3CCC(CC3)C=4N=CC(Cl)=CN4)CCS2=O)C5(CO)CCC5

——

(-20℃)

With Ice Pack

≥ 2 years